QuidelOrtho Has Received FDA 510(k) Clearance For Its Vitros Syphilis Assay. Using The Automated Vitros Systems, This Assay Is Intended For The Qualitative Determination Of Total (IgG and IgM) Antibodies To Treponema Pallidum-specific Antigens In Human Serum And Plasma
Portfolio Pulse from Benzinga Newsdesk
QuidelOrtho has received FDA 510(k) clearance for its Vitros Syphilis Assay, which is used for detecting antibodies related to syphilis infection. This assay is now available globally where QuidelOrtho products are sold.
August 29, 2024 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
QuidelOrtho's Vitros Syphilis Assay has received FDA 510(k) clearance, enhancing its product portfolio and potentially increasing market reach.
The FDA clearance for the Vitros Syphilis Assay is a significant regulatory milestone for QuidelOrtho, likely to enhance its product offerings and market reach. This could positively impact the company's stock price in the short term as it expands its diagnostic capabilities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100